ERBB2 and neoplasm: In this group of individuals, OR (33 vs 11%, P=0.063), DCR (56 vs 36%, P=0.28), TTP (7.7 vs 2.9 months, P=0.1) and OS (13.8 vs 10.9 months, P=0.63) were not significantly different from patients with tumours HER2− and/or HER3−.